| Document |
Document Title |
|
WO/2004/000826A1 |
A compound represented by the following formula (I) is reacted with a trimethyloxosulfonium salt, etc. in the presence of a base to obtain a compound (II). The compound (II) is converted into a compound (IV). The compound (IV) is reacted...
|
|
WO/2004/000808A2 |
Disclosed herein are compounds of Formula I, or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine recept...
|
|
WO/2004/000835A1 |
The invention relates to a method for the production of 1,2,4-triazol-1-yl-methyl-oxiranes of formula (I) wherein A and B are the same or different and independently represent C1-C4-alkyl, phenyl-C1-C2-alkyl,. C3 --C6-cycloalkyl, C3-C6-c...
|
|
WO/2004/000214A2 |
Use of at least one compound having the formula (I), or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in the manufacture of a medicament useful for treating conditions associated with the activity of Factor VIIa is desc...
|
|
WO/2003/106455A1 |
The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein...
|
|
WO/2003/101970A1 |
Imidazolium compounds of formula (I); wherein: A¯ is an anion; R1, R2 and R3 are the same or different and are hydrogen, C1-C6 alkyl, aryl, fused aryl, or heteroaryl; or are substituted aryl, fused aryl or heteroaryl; X and Y are the sa...
|
|
WO/2003/101966A1 |
The invention relates to a method of creating a carbon-carbon or carbon-heteroatom linkage by reacting an unsaturated compound bearing a leaving group and a nucleophilic compound. More specifically, the invention relates to the creation ...
|
|
WO/2003/097612A1 |
The invention relates to substituted 2-phenyl-3(2h)-pyridazinones, to a method for the production thereof, and to their use as medicaments used in the prophylaxis and/or treatment of diseases in humans and/or animals.
|
|
WO/2003/094839A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2003/093249A1 |
The invention relates to thiazolidones of general formula (I), in which R1, R2, R3, X and Y have the meanings as cited in the description and wherein represents an E or Z double bond. The invention also relates to the production of these...
|
|
WO/2003/093231A2 |
The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular...
|
|
WO/2003/088908A2 |
Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating de...
|
|
WO/2003/087110A1 |
The invention relates to a method for producing bis(perfluoroalkyl)phosphinic acids, according to which at least one difluorotris(perfluoroalkyl)phosphorane or at least one trifluorobis(perfluoroalkyl)phosphorane is reacted with hydrogen...
|
|
WO/2003/087111A1 |
The invention relates to a method for producing monohydro-perfluoroalkanes, bis(perfluoroalkyl)phosphinates, and perfluoroalkylphosphonates, according to which at least one perfluoroalkylphosphorane is treated with at least one base in a...
|
|
WO/2003/087106A1 |
The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their u...
|
|
WO/2003/087061A1 |
This invention provides a compound of the formula (I): wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents an alkyl group, etc.; R4 represents an aryl group, et...
|
|
WO/2003/086390A1 |
This invention provides a compound of the formula (1) wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents a hydrogen atom, an alkyl group, etc.; R4 represents a...
|
|
WO/2003/087086A2 |
The invention relates to substituted indoles of formula (I) and to their physiologically safe derivatives and salts, wherein R1, D, E, R12, p, X1, E, G, X2 and Z have the meanings as cited in Claim 1. These substituted indoles and their ...
|
|
WO/2003/086271A2 |
The present invention relates to novel azole derivatives of Formula I, as potential antifungal agents.This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating ...
|
|
WO/2003/087037A1 |
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...
|
|
WO/2003/084916A2 |
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods o...
|
|
WO/2003/082826A1 |
Substituted biaryl amides of Formula I are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic...
|
|
WO/2003/080060A1 |
This invention is directed to substituted piperazine compounds of formula (I) and their pharmaceutically acceptable salts which are useful as antithrombotic agents by inhibiting plasminogen activator inhibitor-1 (PAI-1). In addition, the...
|
|
WO/2003/078404A1 |
There are provided compounds of formula (I), wherein X, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as indicated in claim 1, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades ...
|
|
WO/2003/078426A1 |
The present invention relates to compounds usefull as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositioins comprising said compounds and methods of using the compositions in the treatment o...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/076437A1 |
The invention relates to 2-heteroaryl pyrimidine derivatives of general formula I or If as inhibitors of cyclin-dependent kinasis, the production thereof, and the use thereof as a medicament for treating various diseases.
|
|
WO/2003/076403A1 |
The invention relates to combinatorial libraries containing two or more novel piperidine-3-carboxamide derivative compounds, methods of preparing the piperidine-3-carboxamide derivative compounds and piperidine-3-carboxamide derivative c...
|
|
WO/2003/076406A1 |
Compounds of formula (I) in which each of the phenyl rings represented is optionally substituted one or more times; n represents an integer selected from 0, 1, 2, 3, 4 and 5; W represents -CO-or -SO2-; Z represents H; alkyl; aryl; or ary...
|
|
WO/2003/076424A1 |
The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders...
|
|
WO2002058695A9 |
Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.
|
|
WO/2003/072575A1 |
Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) wherein -N-HET is, for example, (Ic) or (If) wherein R1 is (1-4C)alkyl;Q is selected from, for example, Q1 (Q1) wherein R2...
|
|
WO/2003/072549A1 |
Disclosed are novel tricyclic compounds represented by the formula (1.0) and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical c...
|
|
WO/2003/072033A2 |
The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affi...
|
|
WO/2003/070727A1 |
Selected thiazolyl urea compounds of formula (VI) are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharma...
|
|
WO/2003/070247A1 |
Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
|
|
WO/2003/068770A1 |
The invention relates to R− (−) −1− [2− (7−Chloro−benzo [b] thiophen−3 − yl − methoxy) −2− (2,4−dichloro−phenyl) −ethyl] −1H− imidazole and the salts thereof. The invention also relates to compositions t...
|
|
WO/2003/068738A1 |
Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutic...
|
|
WO/2003/068758A1 |
A process for producing an optically active 2-phenyl-2,3-dihydroxypropylazole derivative which is a compound useful in the fields of medicines and agricultural chemicals and especially is an intermediate extremely important in the produc...
|
|
WO/2003/068725A2 |
A process for preparing 4-substituted phenylalanine ester derivatives is described. Compounds of this type are known to be useful in the preparation of compounds having mixed ACE-NEP inhibitor activity.
|
|
WO/2003/063797A2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating dela...
|
|
WO/2003/064411A1 |
Novel amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing t...
|
|
WO/2003/059289A2 |
Melanin concentrating hormone receptor ligands (especially substituted benzoimidazole analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in ...
|
|
WO/2003/059265A2 |
Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
|
|
WO/2003/059893A1 |
The invention provides N-pyrazinyl-phenylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
|
|
WO/2003/056922A1 |
The invention relates to substituted thiazolyl sulfonyl urea compounds of general formula (I), in which A, R1, R2, R3, R4, and R5 have the meaning indicated in the description, the use of said compounds as herbicides, and a method for pr...
|
|
WO/2003/055868A1 |
The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds o...
|
|
WO/2003/055866A1 |
Quinazoline or quinoline derivatives of formula: (Formula I and II)&semi wherein Z is CH or N&semi Y is O or S&semi X is OR5 or NR5R6&semi R1, R2, R3, R4, R5 and R6 are as disclosed. Also described is a method for the inhibiting the prol...
|
|
WO/2003/053912A1 |
There is provided a series of novel $g(a)-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R?1¿, R?2¿ and R?3¿ are defined herein, which are inhibitors of $g(b)-amyloid peptide ($g(b)-AP) production and are useful in t...
|
|
WO/2003/053918A2 |
The invention relates to a method for producing perfluoroalkane sulfonic acid esters and their subsequent conversion into salts, in addition to the use of the produced compounds in electrolytes and batteries, capacitors, supercapacitors ...
|
